Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity

Infectious Diseases and Therapy

Volumn 3, Issue 2, 2014, Pages 339-347

  Makari, Doris ^a   Jensen, Kathryn M ^a   Harris, Brian ^a   Jafri, Hasan S ^a  

^a MEDIMMUNE   (United States)

Author keywords

Antidrug antibody; Children; Chronic lung disease of prematurity; Liquid; Lyophilized; Palivizumab; Premature infants; Respiratory syncytial virus disease; Safety

Indexed keywords

DRUG ANTIBODY; PALIVIZUMAB;

ABSCESS; ANUS FISSURE; APNEA; ARTICLE; ASPHYXIA; BRONCHIOLITIS; BRONCHOPNEUMONIA; CELLULITIS; CHILD; CHRONIC LUNG DISEASE; CLEFT LIP; COMPARATIVE STUDY; COMPLEX PARTIAL SEIZURE; CONVULSION; CRANIOFACIAL SYNOSTOSIS; CROUP; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FAILURE TO THRIVE; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; HYDRONEPHROSIS; INFANT; INGUINAL HERNIA; LIQUID FORMULATION; LYMPHADENITIS; LYOPHILIZED FORMULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PEDIATRICS; PHASE 4 CLINICAL TRIAL; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; ROTAVIRUS INFECTION; UMBILICAL HERNIA;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84977138105     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0033-y     Document Type: Article

References (15)

1. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–55.
2. American Academy of Pediatrics. Policy statement—modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694–1701.
3. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176:1215–24.
4. Palivizumab. Full prescribing information. Gaithersburg: MedImmune; 2014.
5. La Via WV, Notario GF, Yu XQ, et al. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26:666–71.
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.
7. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791–9.
8. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–40.
9. Mejias A, Chavez-Bueno S, Sanchez PJ. Respiratory syncytial virus prophylaxis. Neoreviews. 2005;6:e26–31.
10. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm. 1993;50:305–14.
11. Data on File—Study MI-CP080. Gaithersburg: MedImmune, LLC.
12. ®), a humanized respiratory syncytial virus monoclonal antibody, in children with a history of prematurity. Gaithersburg: MedImmune, LLC; 2007.
13. Gupta S, Devanarayan V, Finco D, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55:878–88.
14. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35–51.
15. Data on File. Gaithersburg: MedImmune.